| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5886883 | Journal of Critical Care | 2011 | 5 Pages |
Abstract
In the study, prophylactic SC enoxaparin in critically ill patients at the current 30 mg SC twice daily dosage attained an anti-Xa level more than 0.1 U/mL in nearly all patients. In addition, low creatinine clearances and female sex are associated with higher anti-Xa activity AUC0-12h.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Philippe D. MSc (Pharm), Martin MD, Marie-Christine MSc (Pharm), Théodora MSc (Pharm), Isabelle MSc (Pharm), Lucie PhD, David R. MSc (Pharm), BCPS,